Thus our in vitro studies suggest that the effect of commonly used pan-HDAC inhibitors in CTCL cells relies on downstream effects other than DOT1L misregulation. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.